{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:32Z","timestamp":1790312432816,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study evaluated the clinical outcomes and safety of risk-adapted stereotactic body radiotherapy (SBRT) using non-standard fractionation schedules for lung tumors adjacent to organs at risk (OARs). We retrospectively analyzed 81 consecutive patients (92 lesions, 2008\u201325) who received SBRT, including repeat irradiation outside prior fields, with non-standard regimens (56\u00a0Gy\/7 fractions [fr], 50\u00a0Gy\/10 fr, 60\u00a0Gy\/10 fr, 48\u00a0Gy\/6 fr and 35\u00a0Gy\/5 fr). Endpoints included overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), locoregional progression-free survival, local control (LC) and Grade\u2009\u2265\u20093 adverse events. At a median follow-up of 22.2\u00a0months (IQR, 12.1\u201342.9), the median OS was 26.4\u00a0months (95% CI: 17.2\u201343.0), with 1- and 3-year OS rates of 78.6% and 44.1%, respectively. The median PFS was 14.5\u00a0months (95% CI: 9.4\u201321.1), and the median CSS was 43.7\u00a0months (95% CI, 22.7\u201364.4). Median LC was not reached. No significant survival disparities were identified between primary and metastatic cohorts. Grade\u2009\u2265\u20093 toxicities occurred in 10 patients (12.3%), including two Grade 5 events. The 3-year cumulative incidence of Grade\u2009\u2265\u20093 toxicity in ultracentral tumors was 12.6%, with no significant differences among groups. In conclusion, risk-adapted SBRT with increased fractionation demonstrated encouraging LC while maintaining an acceptable toxicity profile for central and ultracentral lung tumors. However, the risk of severe toxicity remains, requiring careful patient selection and optimized OAR dose constraints.<\/jats:p>","DOI":"10.1093\/jrr\/rrag086","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:38:30Z","timestamp":1790311110000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of risk-adapted modified stereotactic body radiotherapy for lung tumors: a single-institution retrospective study"],"prefix":"10.1093","author":[{"given":"Akiko","family":"Oka","sequence":"first","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4804-5737","authenticated-orcid":false,"given":"Hideomi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8093-4649","authenticated-orcid":false,"given":"Subaru","family":"Sawayanagi","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3542-1150","authenticated-orcid":false,"given":"Yuki","family":"Nozawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8051-4137","authenticated-orcid":false,"given":"Daichi","family":"Sugahara","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6675-5245","authenticated-orcid":false,"given":"Takuya","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2258-3130","authenticated-orcid":false,"given":"Tenyoh","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-1828","authenticated-orcid":false,"given":"Atsuto","family":"Katano","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092500382601600_ref1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ijrobp.2015.07.2278","article-title":"Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403","volume":"93","author":"Nagata","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092500382601600_ref2","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026092500382601600_ref3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1186\/s12885-020-07514-9","article-title":"Analyses of the local control of pulmonary oligometastases after stereotactic body radiotherapy and the impact of local control on survival","volume":"20","author":"Yamamoto","year":"2020","journal-title":"BMC Cancer"},{"key":"2026092500382601600_ref4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","article-title":"Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review","volume":"106","author":"Senthi","year":"2013","journal-title":"Radiother Oncol"},{"key":"2026092500382601600_ref5","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026092500382601600_ref6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10147-017-1125-y","article-title":"Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1)","volume":"22","author":"Kimura","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"2026092500382601600_ref7","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jtho.2024.05.366","article-title":"Stereotactic body radiotherapy for centrally located inoperable early-stage NSCLC: EORTC 22113-08113 LungTech phase II trial results","volume":"19","author":"Levy","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026092500382601600_ref8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026092500382601600_ref9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: a safety and efficacy trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092500382601600_ref10","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer","author":"National Comprehensive Cancer Network","year":"2026"},{"key":"2026092500382601600_ref11","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.jtho.2024.09.1386","article-title":"Appropriate use criteria (AUC) for the management of non-small cell lung cancer in a central\/ultra-central location: guidelines from the American Radium Society","volume":"19","author":"Park","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026092500382601600_ref12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with ``ultracentral'' non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026092500382601600_ref13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.radonc.2019.01.035","article-title":"Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours","volume":"134","author":"Lenglet","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026092500382601600_ref14","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1111\/cas.14185","article-title":"Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer","volume":"110","author":"Meng","year":"2019","journal-title":"Cancer Sci"},{"key":"2026092500382601600_ref15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3857\/roj.2021.00416","article-title":"Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer","volume":"39","author":"Yoo","year":"2021","journal-title":"Radiat Oncol J"},{"key":"2026092500382601600_ref16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13014-023-02298-1","article-title":"Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity","volume":"18","author":"Rock","year":"2023","journal-title":"Radiat Oncol"},{"key":"2026092500382601600_ref17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13014-020-01491-w","article-title":"Outcomes of stereotactic body radiotherapy 60\u2009Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors","volume":"15","author":"Zhao","year":"2020","journal-title":"Radiat Oncol"},{"key":"2026092500382601600_ref18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cllc.2020.11.003","article-title":"Safety and efficacy of stereotactic body radiotherapy in ultracentral lung tumors using a risk-optimized fractionation scheme","volume":"22","author":"Regnery","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2026092500382601600_ref19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2024.3089","article-title":"Stereotactic vs hypofractionated radiotherapy for inoperable stage I non-small cell lung cancer: the LUSTRE phase 3 randomized clinical trial","volume":"10","author":"Swaminath","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026092500382601600_ref20","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/j.prro.2018.09.003","article-title":"Impact of tumor size on local control and pneumonitis after stereotactic body radiation therapy for lung tumors","volume":"9","author":"Parker","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"2026092500382601600_ref21","doi-asserted-by":"publisher","first-page":"30076","DOI":"10.1038\/s41598-024-73177-2","article-title":"Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"2026092500382601600_ref22","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.ijrobp.2023.06.246","article-title":"Expanded HILUS trial: a pooled analysis of risk factors for toxicity from stereotactic body radiation therapy of central and ultracentral lung tumors","volume":"117","author":"Lindberg","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092500382601600_ref23","doi-asserted-by":"publisher","first-page":"110605","DOI":"10.1016\/j.radonc.2024.110605","article-title":"Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: a secondary analysis of the LUSTRE randomized trial","volume":"202","author":"Wu","year":"2025","journal-title":"Radiother Oncol"},{"key":"2026092500382601600_ref24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/jrr\/rraf016","article-title":"Stereotactic body radiotherapy for central non-small cell lung cancer: risk analysis of radiation pneumonitis and bronchial dose constraints","volume":"66","author":"Kita","year":"2025","journal-title":"J Radiat Res"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/advance-article-pdf\/doi\/10.1093\/jrr\/rrag086\/71384489\/rrag086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/advance-article-pdf\/doi\/10.1093\/jrr\/rrag086\/71384489\/rrag086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:38:44Z","timestamp":1790311124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/advance-article\/doi\/10.1093\/jrr\/rrag086\/8834139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrag086","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"rrag086"}}